OpenEvidence Strikes Multi-Year Deal to Embed AUA Guidelines in Its AI Clinical Platform

New updates have been reported about OpenEvidence.

OpenEvidence has signed a multi-year collaboration with the American Urological Association (AUA) to embed AUA Clinical Practice Guidelines and Clinical Consensus Statements directly into its AI-driven clinical decision support platform. The integration positions OpenEvidence more deeply inside point-of-care workflows for urologists and other clinicians managing urologic conditions, enhancing the platform’s value as a front-line tool for evidence-based decision-making.

By incorporating AUA’s society-developed guidance, OpenEvidence strengthens its differentiation around authoritative, citation-based content at a time when health systems are scrutinizing the rigor of AI tools used in clinical care. The agreement also gives AUA usage and gap-analysis data on how guidelines are applied in practice, which in turn should help OpenEvidence refine product features and analytics that track real-world utilization of clinical guidance.

AUA leadership framed the partnership as a deliberate move to shape, rather than react to, the growing influence of AI in clinical decision-making, underscoring the importance of maintaining guideline integrity within AI-enabled tools. For OpenEvidence, this relationship both validates its model of working directly with leading medical societies and helps mitigate regulatory and reputational risk by anchoring AI outputs in vetted standards.

Travis Zack, Chief Medical Officer of OpenEvidence, emphasized that AI systems in medicine must rest on established professional guidelines to be trusted for high-stakes decisions, aligning the company’s product strategy with medical society expectations. The deal should deepen OpenEvidence’s penetration among urologists, support cross-specialty adoption where urologic conditions are managed by primary care, and strengthen its positioning as a preferred platform for other societies seeking controlled distribution and feedback on guideline use.

Strategically, the partnership enhances OpenEvidence’s content moat and could support pricing power with enterprise customers that prioritize guideline-concordant care and risk management. Over time, aggregated data on guideline usage and gaps may open incremental revenue opportunities in analytics and quality-improvement solutions, while also informing product development to support evolving standards of care in urology and beyond.